Similar articles

• Exemestane or tamoxifen?

  Ueda M, Toji E, Noda S. Ueda M, et al. Lancet. 2007 May 12;369(9573):1600; author reply 1600-1. doi: 10.1016/S0140-6736(07)60741-7. Lancet. 2007. PMID: 17499595 No abstract available.
• Switching to aromatase inhibitors in early breast cancer.

  Boccardo F, Rubagotti A. Boccardo F, et al. Lancet. 2007 Feb 17;369(9561):533-5. doi: 10.1016/S0140-6736(07)60201-3. Lancet. 2007. PMID: 17307082 No abstract available.
• [New strategies against breast carcinoma. To outwit the resistance tendency of tumor cells].

  Jakesz R. Jakesz R. MMW Fortschr Med. 2005 Mar 10;147(10):8. MMW Fortschr Med. 2005. PMID: 15803774 German. No abstract available.
• Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.

  Jahanzeb M. Jahanzeb M. Clin Ther. 2007 Aug;29(8):1535-47. doi: 10.1016/j.clinthera.2007.08.013. Clin Ther. 2007. PMID: 17919537 Review.
• A review of exemestane in the management of breast cancer.

  Wong NS, Pritchard KI. Wong NS, et al. Expert Opin Pharmacother. 2005 Oct;6(13):2353-63. doi: 10.1517/14656566.6.13.2353. Expert Opin Pharmacother. 2005. PMID: 16218894 Review.